Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
ISSN: 2376-0419
Hisahiro Mori
Fujifilm Corporation, Japan
Scientific Tracks Abstracts: J Pharma Care Health Sys
Introduction: Fujifilm has been developing microneedle array (MNA) of dissolvable type, from 2011. Followings 2 topics were investigated and published. For future aseptic mass production, Fujifilm owns the facility for manufacturing investigational new drug (capable for aseptic production) and developing mass production technologies. In this presentation, results of animal experiments are mainly reported. 1st topic: MNA incorporating influenza vaccine Ether-split and whole virus particles inactivated with formalin were prepared from two type of influenza virus, A/Puerto Rico/8/1934 (H1N1) (PR8) and A/duck/Hokkaido/Vac-3 (H5N1) (Vac-3). These vaccines were incorporated in MNA. BALB/c mice were vaccinated by MNA or subcutaneous injection. MNA containing ether-split or whole virus particle of PR8 shown higher neutralizing antibodies than subcutaneous injection. MNA containing PR8 of whole virus particle shown immunogenicity at lower vaccine dose, compared to MNA containing PR8 of ether split. Furthermore, survival rates of MNA vaccinated mice were significantly higher than subcutaneously vaccinated mice. Virus titer in lung correlated with neutralizing antibody titer in serum. Similar results were obtained with Vac-3. 2nd topic: MNA incorporating hepatitis B surface antigen (HBsAg) HBsAg was incorporated into MNA with or without adjuvant (saponin QS-21). Yorkshire/Landrace F1 (Y x L) x Duroc swine were vaccinated by MNA or intramuscular injection. Commercial HBsAg vaccine containing Al(OH)3 as adjuvant (Engerix-B) was used as a reference. Non-adjuvanted MNA boost after priming with Engerix-B was non-inferior to the benchmark (twice Engerix-B). MNA worked as booster vaccine, without the use of an adjuvant. However, single MNA priming did not elicit an anti-HBsAg antibody response. For QS-21 adjuvanted MNA, twice MNA administration was non-inferior to the benchmark (twice Engerix-B). Also, single MNA priming was able to elicit an anti-HBsAg antibody response.
Hisahiro Mori is responsible for formulation design of dissolvable MNA and he is developing MNA containing various vaccines or hormones. His aim is to provide MNA to patients, in order to contribute to prevention and treatment of disease. Dissolvable MNA has the merit of safety (no risk of needle-stick injury) and high efficacy, expected improvement in QOL.
E-mail: hisahiro.mori@fujifilm.com